참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Bromobenzene | HCID 7961 | — |
| 반응물 | 7-Azaspiro[3.5]nonan-2-yl-(4-cyclobutylpiperazin-1-yl)methanone | HCID 59333133 | — |
| 시약 | Cesium carbonate | HCID 10796 | — |
| 촉매 | Binap, (A+-)- | HCID 634876 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 용매 | Toluene | HCID 1140 | — |
| 생성물 | (4-Cyclobutylpiperazin-1-yl)-(7-phenyl-7-azaspiro[3.5]nonan-2-yl)methanone | HCID 46212800 | 46.78% |
반응 단계
cesium carbonate (123 mg, 0.38 mmol) was added to a solution of (4-cyclobutylpiperazin-1-yl)(7-azaspiro[3.5]nonan-2-yl)methanone (100 mg, 0.34 mmol), PdOAc2 (7.70 mg, 0.03 mmol), BINAP (42.7 mg, 0.07 mmol) and bromobenzene (56.6 mg, 0.36 mmol) in toluene (5 mL). The reaction mixture was heated to 110°C for 18hrs. The room temperature cooled down mixture was filtered over celite. The solvent was concentrated. The product was purified by preparative HPLC using a low pH shallow gradient method (Mobile phase: 20-40% B; A: H2O with 0.05% TFA , B: CH3CN, 25 min. run) on Luna 15 m, C8 (2), 21.2x250 mm Phenomenex reverse phase column to provide (4-cyclobutylpiperazin-1-yl)(7-phenyl-7-azaspiro[3.5]nonan-2-yl)methanone (59.0 mg, 46.8 %) as white solid. 1H NMR (400 MHz, CHLOROFORM- _d_ ) d ppm 1.60 - 1.75 (m, 4 H) 1.75 - 1.81 (m, 2 H) 1.81 - 1.95 (m, 2 H) 1.96 - 2.10 (m, 4 H) 2.10 - 2.20 (m, 2 H) 2.21 - 2.35 (m, 4 H) 2.71 (dq, _J_ =8.01, 7.75 Hz, 1 H) 3.00 - 3.11 (m, 2 H) 3.11 - 3.26 (m, 3 H) 3.31 - 3.42 (m, 2 H) 3.56 - 3.70 (m, 2 H) 6.82 (t, _J_ =7.23 Hz, 1 H) 6.93 (d, _J_ =7.81 Hz, 2 H) 7.18 - 7.29 (m, 2 H) HRMS _m/z_ calcd for C23H33N3O 368.26964 [M+H]+, found 368.26981. MS _m/z_ 368.3 [M+H]\+ (ES+)
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-2bde997c68344c96991dffb75b1f4b33 |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|